Interactions of trace elements: clinical significance.
We examined interaction of the trace element zinc with copper and lead. In sickle cell anemia, the usual situation is one of mild to moderate zinc deficiency owing to renal loss of zinc. Zinc deficiency seems to produce a mild overburden of copper and an increased ceruloplasmin level, probably by enhancing copper absorption. With zinc therapy, this process is reversed. Pharmacological doses of zinc, when administered in a way to ensure effectiveness (without food) will usually lead to copper deficiency. We have taken advantage of the copper-depleting effect of zinc to design a new therapy for Wilson's disease. Zinc, by inducing intestinal metallothionein, inhibits absorption of copper from food, and inhibits reabsorption of endogenously secreted copper, thereby producing a negative copper balance in Wilson's disease. Once we are certain that zinc blocks accumulation of copper in the liver of Wilson's disease patients, zinc therapy will be available as one approach for treating this fatal disease. The animal literature indicates that zinc protects against lead toxicity when both elements are given orally, no doubt through the intestinal metallothionein mechanism. In preliminary experiments in rats, we have not been able to show that toxicity from lead that arrives into the body through a nonoral route is affected by oral zinc supplements.
D000755:Anemia, Sickle Cell / Q000188:drug therapy; D002570:Ceruloplasmin / Q000096:biosynthesis; D003300:Copper / Q000172:deficiency / Q000378:metabolism / Q000502:physiology; D004347:Drug Interactions; D006527:Hepatolenticular Degeneration / Q000188:drug therapy; D006801:Humans; D007854:Lead / Q000378:metabolism; D014131:Trace Elements / Q000502:physiology*; D015032:Zinc / Q000009:adverse effects / Q000378:metabolism / Q000502:physiology / Q000627:therapeutic use
D014131:Trace Elements; D007854:Lead; D003300:Copper; D002570:Ceruloplasmin; D015032:Zinc